Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

<i>APOE</i> Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline.

Journal of Korean medical science·2026
Same author

Nano formulation of Sophora japonica extract stimulates osteogenic activity in osteoblasts.

Journal of food science and technology·2026
Same author

Mixing-sequence-governed dispersion and processability of electrode slurries with carboxymethyl cellulose and cellulose nanofibrils.

Carbohydrate polymers·2026
Same author

A clinically feasible framework to estimate tau pathology and clinical-biological discordance in the Alzheimer's disease spectrum.

Alzheimer's research & therapy·2026
Same author

Prediction of cognitive impairment through speech data analysis: A comparative evaluation of deep learning models.

PloS one·2026
Same author

Reversibility of cognitive and psychiatric impairments following surgical resection of frontotemporal meningiomas: a predictive factor analysis.

BMC neurology·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Fred Kim1, Tianyang Xi1, Han Joo Lee2

  • 1AriBio Co., Ltd., San Diego, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

作为阿尔茨海默病 (AD) 单一疗法,AR1001 (米罗迪纳菲尔) 是一个有前途的药物. 在一项2期试验中,30毫克AR1001显著改善了不服用其他AD药物的患者的认知能力,并减少了AD生物标志物.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.
  • 生物标志物 生物标志物

背景情况:

  • AR1001 (米罗迪纳菲尔) 是一种用于阿尔茨海默病 (AD) 的实验性口服固醇酶5 (PDE5) 抑制剂.
  • 一项2期试验评估了AR1001在轻度至中度AD患者的安全性和有效性.
  • 在26周的时间内,AR1001在10毫克和30毫克剂量下显示出可接受的安全性.

研究的目的:

  • 评估AR1001在轻度至中度AD患者的安全性和有效性.
  • 评估AR1001对认知功能和AD生物标志物的影响.
  • 探索AR1001作为AD的单一疗法的潜力.

主要方法:

  • 这是一项双盲,随机,安慰剂对照试验,涉及210名轻度至中度AD患者.
  • 参与者每天接受安慰剂,10毫克AR1001或30毫克AR1001的口服剂量,持续26周.
  • 亚组分析检查了基于同时使用AD药物的效应,重点是ADAS-Cog-13和血生物标志物 (ptau-181,ptau-217).

主要成果:

  • 虽然主要终点 (ADAS-Cog-13) 整体上没有显著差异,但与安慰剂相比,30毫克AR1001组显示血ptau-181和ptau-217减少.
  • 在没有同时服用AD药物的参与者中,30毫克AR1001单疗对ADAS-Cog-13 (p=0.012) 呈现了统计学上显著的改善.
  • 与安慰剂相比,AR1001 30mg单疗也导致血ptau-181 (p=0.023) 和ptau-217 (p<0.05) 的显著降低.

结论:

  • 30毫克的AR1001 (米罗德纳菲尔) 证明了作为阿尔茨海默病单一治疗的潜力.
  • 亚组分析表明,在没有其他AD药物的情况下接受AR1001 30mg治疗的患者经历了认知效益.
  • 该研究强调了AR1001通过减少关键的病理生物标志物来改变AD进展的潜力.